A Look At Jazz Pharmaceuticals (JAZZ) Valuation As New Oncology Data Heads To The 2026 AACR Meeting

Jazz Pharmaceuticals (JAZZ) highlighted its oncology pipeline with plans for one oral and six poster presentations at the 2026 AACR meeting, featuring new data on zanidatamab, JZP898, and dordaviprone.

See our latest analysis for Jazz Pharmaceuticals.

The AACR pipeline update comes as Jazz Pharmaceuticals’ share price sits at US$180.45, with a 30 day share price return of 8.5% and a 1 year total shareholder return of 27.01%, suggesting momentum has recently strengthened after a softer week.

If this oncology news has you thinking about the wider healthcare opportunity, it can be useful to compare against other names shaping the space through 35 healthcare AI stocks

With JAZZ trading at US$180.45, showing a 27.0% one-year total return and trading below analyst price targets and intrinsic estimates, is the stock still underappreciated, or is the market already pricing in future growth?

Most Popular Narrative: 21.2% Undervalued

According to Vestra, the fair value for Jazz Pharmaceuticals at $228.98 sits well above the last close of $180.45. This frames JAZZ as a value gap story built on cash generation and oncology execution.

Jazz Pharmaceuticals has officially entered a new era of “blockbuster” diversification, closing out 2025 with its highest quarterly revenue ever. On February 24, 2026, the company reported Q4 revenue of $1.20 billion, a 10% year-over-year increase that beat analyst estimates.

Read the complete narrative.

Want to see what actually underpins that valuation gap? The narrative leans on a rare mix of blockbuster neurology cash flows, oncology catalysts, and a forward earnings profile usually reserved for larger pharma. Curious which growth, margin, and earnings assumptions have to hold for that fair value to make sense?

Result: Fair Value of $228.98 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on continued execution in oncology and sleep, with any setback in zanidatamab approvals or further erosion in legacy Xyrem potentially challenging that valuation gap.

Find out about the key risks to this Jazz Pharmaceuticals narrative.

Next Steps

With both risks and rewards in play, does the story so far feel balanced enough for your tastes, or too reliant on assumptions? Act while the data is fresh in your mind and weigh the upside against the downside with 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If JAZZ has your attention, do not stop here. Broaden your watchlist with other focused ideas that could sharpen your portfolio and highlight fresh opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com